Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Anatomy
- Nutrition and Food Science
- Internal Medicine
- Anesthesiology and Pain Medicine
- Dentistry and Oral Biology
- Sports Medicine
- Lung Cancer
- Renal Disease
Abstract
Citation: Ann Clin Case Rep. 2016;1(1):1130.DOI: 10.25107/2474-1655.1130
HBV Reactivation in a Non-Hodgkin Lymphoma Patient with Resolved HBV Receiving Rituximab Maintenance Therapy
Chen YT, Chang CH, Yeh HZ Chang CS and Yang SS
Division of Gastroenterology & Hepatology, Feng Yuan Hospital of the Ministry of Health & Welfare, Taichung, Taiwan
Division of Gastroenterology & Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan
Department of Medicine, Chung-Shan Medical University, Taichung, Taiwan
PDF Full Text Case Report | Open Access
Abstract:
Introduction: Rituximab induced hepatitis B virus (HBV) reactivation in both HBsAg-positive and HBsAg-negative chronic hepatitis B patients had been reported. Among these studies, most rituximab therapy was concomitant with chemotherapy including steroid. Whether rituximab maintenance monotherapy could induce HBV reactivation and resulting in serious complications is unknown.Case Presentation and
Conclusion: We report one patient who has negative hepatitis B surface antigen (HBsAg-negative) and positive antibodies to hepatitis B surface antigen (anti-HBs-positive) prior to rituximab-containing chemotherapies develops HBV reactivation followed by fulminant hepatic failure when he was undergoing rituximab maintenance therapy. Patients with resolved HBV, rituximab-based regimen induces reactivation of hepatitis B more frequent than other chemotherapy regimens, and those patients have a higher rate of mortality compared to HBsAgpositive cohorts in the mean while. Monitoring serum ALT level monthly with HBV serology check-up mainly HBsAg (and/or serum HBV DNA) every 3 months in those patients undergoing rituximab-based chemotherapy are highly recommended.
Keywords:
Hbv Reactivation; Resolved Hbv; Rituximab; Lymphoma
Cite the Article:
Chen YT, Chang CH, Yeh HZ, Chang CS, Yang SS. HBV Reactivation in a Non-Hodgkin Lymphoma Patient with Resolved HBV Receiving Rituximab Maintenance Therapy. Ann Clin Case Rep. 2016; 1: 1130.
